Results 81 to 90 of about 23,420 (253)
cfDNA-Based NGS IG Analysis in Lymphoma
, 2022 AbstractLiquid biopsy is a novel diagnostic approach at first developed to characterize the molecular profile of solid tumors by analyzing body fluids. For cancer patients, it represents a noninvasive way to monitor the status of the solid tumor with respect to representative biomarkers. There is growing interest in the utilization of circulating tumor Christiane, Pott, Michaela, Kotrova, Nikos, Darzentas, Monika, Brüggemann, Mouhamad, Khouja +4 moreopenaire +2 more sourcesSizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer
International Journal of Cancer, EarlyView.What's New?
This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...Anouchka Modesto, Sophie Gibert, Caroline Delmas, David Tougeron, Amaury Paumier, Alexandre Taillez, Samuel Le Sourd, Delphine Argo Leignel, Philippe Ronchin, Ariane Darut Jouve, Véronique Vendrely, Olivier Riou, Jérôme Martin‐Babau, Thomas Leroy, Laurent Quéro, Naïma Hanoun, Pierre Cordelier, Veronica Pezzella, Jean Pierre Delord, Rosine Guimbaud, Elizabeth Moyal, Catherine Seva +21 morewiley +1 more sourceA Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients
International Journal of Cancer, EarlyView.Long non‐coding RNAs (lncRNAs) signatures are promising cancer biomarkers, since their dysregulation in tumors is reflected in body fluids. In this study, next‐generation sequencing, bioinformatics, and gene expression data were combined to investigate an lncRNA signature linked specifically to the cancer‐promoting YAP in several cancer types ...Fabian Rose, Nada El‐Ekiaby, Lilija Wehling, Sofia Maria Elisabeth Weiler, Jennifer Schmitt, Marcell Tóth, Fabiola Pedrini, Amruta Damle‐Vartak, Carsten Sticht, Rossella Pellegrino, Injie Omar Fawzy, Merna Hatem Mohamed Hamad, Mohamed Negm, Dina Omar, Hossam Eldeen Soliman, Gamal Esmat, Thomas Longerich, Thomas Illig, Bruno Christian Köhler, Anna Saborowski, Heike Bantel, Arndt Vogel, Peter Schirmacher, Ahmed Ihab Abdelaziz, Kai Breuhahn +24 morewiley +1 more sourcePreanalytical factors in cfDNA analysis [PDF]
, 2018 Karcinom dojke najučestalije je maligno oboljenje u Hrvatskoj, a dijagnoza se vrlo često postavlja kasno što utječe na daljnji tijek bolesti. Važno je poboljšati laboratorijsku dijagnostiku da bi se otkrile i standardizirale metode koje bi omogućile ...Hlapčić, Ivacore Integrity of cfDNA and a corresponding sequencing library.
, 2016 (A) Integrity and size distribution of cfDNA fragments from patient 1 showing a nucleosomal laddering of cfDNA with fragment sizes of 166, 360, and 515 bp; (B) Corresponding sequencing library from patient 1, prepared from 10ng cfDNA.Clémentine Mercé (2966898), Steffen Dietz (2966895), Michael Meister (120830), Thomas Muley (87877), Holger Sültmann (214717), Uwe Schirmer (607461), Nikolas von Bubnoff (199425), Michael Thomas (377350), Edgar Dahl (42758) +8 morecore +1 more sourcePredictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study
International Journal of Cancer, EarlyView.Bevacizumab added to systemic chemotherapy remains a cornerstone of metastatic colorectal cancer treatment, but its effectiveness is variable. Tumors can bypass the VEGF blockade by activating other pro‐angiogenic pathways, hampering the identification of predictive biomarkers.Büsra Akay Hacan, Fatma Gizem Sonugür, Müge Öçal, Cansu Babahan, Samira Abgarmi, Ülkü Yalçıntaş Arslan, Mehmet Ali Şendur, Ahmet Demirkazık, Güngör Utkan, Hakan Akbulut +9 morewiley +1 more sourcePancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium
International Journal of Cancer, EarlyView.ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms ...Christine Worthington, Maria Raitses‐Gurevich, Giulio Innamorati, Phil A. Hart, Thomas M. Wilkie, Noam Tau, Dana Brin, Doron Yablecovitch, Ido Laish, Dove Keith, Kurt Giles, Jennifer B. Permuth, Diane M. Simeone, George Zogopoulos, Randall E. Brand, John J. Graff, Julie Earl, On behalf of the PRECEDE Consortium, Nikhil Agarwal, Laufey Amundadottir, Michelle Anderson, Ajay Bansal, Todd Bauer, Georg Beyer, Yan Bi, Erkut Borazanci, Randy Brand, Teri Brentnall, Carol Burke, Darren Carpizo, Saurabh Chawla, Daniel Chung, Sourat Darabi, Michael Demeure, Timothy Donahue, Julie Earl, Whitney Espinel, James Farrell, Vigdís Fjóla Stefánsdóttir, Jared Forrester, Eitan Friedman, Paul Franklin, Srinivas Gaddam, Ana García García de Paredes, Steven Gallinger, Talia Golan, Ora Gordon, Robert Grant, William Greenhalf, Eli Marie Grindedal, Aaron Grossberg, Brenda Hafers, Heather Hannon, Sigurdís Haraldsdóttir, Stefán Haraldsson, Peter Hegyi, Melissa Hogg, Amy de Haar‐Holleman, Susan Hong, Greg Idos, Edward Kim, Fay Kastrinos, Bryson Katona, Vivek Kaul, Derk Klatte, Kelsey Klute, Kimberly Ku, Sonia Kupfer, Rich Kwon, Rosario Ligresti, James James Lin, Wei‐Chih (David) Liao, Aimee Lucas, Nipun Merchant, Andrew Metz, Whitney Maxwell, James McLoughlin, Sodech Miclette, Xavier Molero, Leticia Moreira, Takuji Okusaka Chigusa Morizane, Joanne Ngeow, Salvatore Paiella, Jennifer Permuth, Maricel Purcell, Joshua Raff, Vineet Rolston, Intan Schrader, Rosie Sears, Yan‐Shen Shan, Diane Simeone, Jens Siveke, Brett Sheppard, Tyler Stevens, Elena Stoffel, Dan Sussman, Margaret Tempero, Jose Trevino, Jennifer Valerin, Eva Vaquero, Ray Wadlow, Garrett Ward, David Weinberg, Ronald Wolf, Dana Zakalik, George Zogopoulos +105 morewiley +1 more sourceEach family has its own unique cfDNA level.
, 2019 The mean plasma cell-free (cfDNA) concentration (ng/ml) measured by Qubit fluorometer for individual families (n = 77) is shown in a scatter plot where each dot represents the mean cfDNA value for a single family.Serdar Coskun (738308), Lamyaa Alghofaili (7485176), Syed S. Islam (7485185), Bedri Karakas (738305), Khawlah Gassem (7485182), Hannah Almubarak (7485179), Namik Kaya (347797) +6 morecore +1 more sourceSequencing metrics of urine cfDNA in healthy adults.
, 2021 cfDNA, cell-free DNA. (XLSX)Jeffrey J. Szymanski (11361789), Brian C. Baumann (7431935), Faridi Qaium (11361786), Melissa A. Reimers (11361792), Vivek K. Arora (5702474), Ramandeep K. Babbra (11361765), Wenjia Feng (11361768), Katherine Dienstbach (11361777), Eric H. Kim (4060258), Zachary L. Smith (11361795), Pradeep S. Chauhan (2618257), Kevin Chen (264284), Li Ding (16240), Armaan Nallicheri (11361774), Nadja Pejovic (11361771), Lenon Maguire (11361783), Dengfeng Cao (6382949), Andrew Atkocius (11361780), Aadel A. Chaudhuri (11361798), Peter K. Harris (2312653) +19 morecore +1 more sourcePlasma cfDNA as a Potential Biomarker to Evaluate the Efficacy of Chemotherapy in Gastric Cancer
Cancer Management and Research, 2020 Yuejiao Zhong,1,* Qingyu Fan,2,* Zhaofei Zhou,1 Yajing Wang,1 Kang He,1 Jianwei Lu1 1Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People’s Republic of ...Zhong Y, Fan Q, Zhou Z, Wang Y, He K, Lu J +5 moredoaj
